Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and ...
Clinical Trials Arena on MSN
Ultragenyx doses first subject in study of GTX-102 for angelman syndrome
"Ultragenyx doses first subject in study of GTX-102 for angelman syndrome" was originally created and published by Clinical ...
As a powerful Hurricane Melissa continued its destructive path through the Caribbean and into the Atlantic on Wednesday, Jamaica began the arduous task of trying to assess what one United Nations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback